Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study is a research paper published in PLoS Medicine (2021). On theSindex it has a DataRank of 1.1. It has been cited 25 times, with 18 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.489
From this paper's citation signal
Citation Network Contribution
0.566
From 17 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 18 citers.
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI069412
National Institute of Allergy and Infectious Diseases
Grant: 2UM1AI069534
National Institute of Allergy and Infectious Diseases
Grant: UM1AI148452
National Institute of Allergy and Infectious Diseases
Grant: 2P30-AI-045008
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068614-14
NIAID NIH HHS
Grant: UM1 AI069534
NIAID NIH HHS
Grant: UM1 AI068614
NIAID NIH HHS
Grant: UM1 AI068635
NIAID NIH HHS
Grant: S10 AI174104
NIAID NIH HHS
Grant: P30 AI045008
NIAID NIH HHS
Grant: UM1 AI068617
National Institutes of Health
Grant: 2UM1AI069412-08
Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)
National Institutes of Health
Grant: 5UM1AI069534-19
University of Pennsylvania HIV Clinical Trials Unit
National Institutes of Health
Grant: 3UM1AI068614-15S2
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
National Institutes of Health
Grant: 5P30AI045008-10
Core--Immunology Facility
National Institutes of Health
Grant: 5UM1AI148452-02
Vanderbilt Vaccine and Treatment Evaluation Unit
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Sustained seropositivity up to 20.5 months after COVID-19
Additional file 1 of Sustained seropositivity up to 20.5 months after COVID-19